Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for UK-based media Merck and Pfizer Inc. (NYSE: PFE) today announced results from the Phase III JAVELIN Lung 200 trial comparing avelumab* to docetaxel in patients with unresectable, recurrent or metastatic non-small cell lung cancer (NSCLC) whose ...
Lausanne (ots) - Debiopharm Group (TM) announces an investment in antibiotic development with the acquisition of a minority stake in ABAC Therapeutics Inc. This investment was made through the Debiopharm Innovation Fund, its strategic investment fund, and illustrates the synergy between the group companies in the ...
Bagsværd, Denmark (ots/PRNewswire) - Results from the SUSTAIN 7 trial, which investigated the efficacy and safety of 0.5 mg semaglutide compared with 0.75 mg dulaglutide and 1.0 mg semaglutide compared with 1.5 mg dulaglutide, when added to metformin, have been published in The Lancet Diabetes & Endocrinology.[1] ...
Haifa, Israel and Miami (ots/PRNewswire) - INSIGHTEC, a commercial-stage medical technology company revolutionizing surgery with incisionless MRI-guided focused ultrasound (MRgFUS) announced today the closing of a $150 million Series E private equity investment round. Koch Disruptive Technologies (KDT), a subsidiary of Koch Industries, focused on finding and funding innovative and emerging companies, led the round with a ...
Sunnyvale, California (ots/PRNewswire) - CyberKnife Frameless Radiosurgery Offers a Precise and Non-Invasive Technique with Clinical Outcomes Similar to Gamma Knife Frame-Based Invasive Radiosurgery Accuray Incorporated (NASDAQ: ARAY) announced today that data from a study of 138 patients with trigeminal neuralgia (TN) showed stereotactic radiosurgery (SRS) delivered ...
Loures, Portugal (ots/PRNewswire) - Hovione announced that a new MG2 Tekna Precision Capsule filling unit is now online in its Portugal facilities. This investment reinforces Hovione's Services portfolio in inhalation product development capabilities (http://www.hovione.com/products-and-services/contract-manufacturing-services/drug-product/innovation-and-expertise), which include proprietary particle engineering ...
Almere, The Netherlands (ots/PRNewswire) - Emotional Brain is pleased to announce the publication of positive phase 2B results in the authoritative Journal of Sexual Medicine (http://www.jsm.jsexmed.org/article/S1743-6095(17)31851-9/fulltext). Lybrido and Lybridos were successfully tested in 497 women with Female ...
Brussels (ots/PRNewswire) - - European Medicines Agency (EMA) has approved label change for UCB's CIMZIA® (certolizumab pegol), making it the first anti-TNF for potential use in women with chronic rheumatic disease, during both pregnancy and breastfeeding - Data submitted to regulatory authorities included ...
Hombrechtikon Systems Engineering AG
Darmstadt, Germany and New York (ots/PRNewswire) - - Second Breakthrough Therapy Designation for avelumab in hard-to-treat cancer - Renal cell carcinoma, the most common form of kidney cancer, has a poor prognosis in advanced stage[1],[2] - Javelin Renal clinical development program is ongoing, including Phase III ...
Odense, Denmark, and Smiths Falls, Ontario (ots/PRNewswire) - Further to a December 5th press release announcing plans to establish a 40,000 m2 facility in the Danish city of Odense, Spectrum Cannabis Denmark has been issued a cannabis production licence by Laegemiddelstyrelsen, Denmark's Medicines Agency. Danish Health Minister, Ellen Trane Nørbye, announced the news ...
European Society for Medical Oncology (ESMO)
Lugano (ots) - ESMO, the leading professional organisation for medical oncology, published a position paper on supportive and palliative care, calling attention to the evolving and growing gap between the needs of cancer patients and the actual provision of patient-centred care. "New studies show that there may be a gap between what doctors think is important for patients, and what patients really need. With this position ...
Munich (ots/PRNewswire) - For EU media only - not for US journalists - Hokusai-VTE CANCER study is a phase 3b, prospective, randomised, open-label, blind end-point (PROBE) study evaluating edoxaban versus low molecular weight heparin (LMWH) dalteparin in venous thromboembolism (VTE) associated with primarily active ...
Bagsværd, Denmark (ots/PRNewswire) - - Results published in Diabetes, Obesity and Metabolism Newly published data from real-world European clinical practice has shown that Xultophy® (insulin degludec/liraglutide) significantly reduced blood sugar levels in people with type 2 diabetes after six months.[1] The study ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for U.K./U.S. based media - First treatment in relapsing-remitting multiple sclerosis (RRMS) to show sustained clinical efficacy for up to 4 years with a maximum of 20 days of oral treatment over 2 years - Updated registration follows recent approval of Mavenclad in Europe and Canada Merck, a leading science and ...
Abu Dhabi, Uae (ots/PRNewswire) - In people with type 2 diabetes who fast during Ramadan, Ryzodeg® (insulin degludec/insulin aspart) reduced the overall rate of low blood sugar (hypoglycaemia) including severe episodes by 62% and the rate of nocturnal hypoglycaemia by 74% versus biphasic insulin aspart 30 (BIAsp 30 ...
Abu Dhabi, Uae (ots/PRNewswire) - People with either type 1 or type 2 diabetes treated with Tresiba® had fewer episodes of low blood sugar (hypoglycaemia) compared with people on insulin glargine U100 regardless of whether they had achieved blood sugar targets.[1] These new post-hoc analyses from the SWITCH 1 and 2 trials were presented at the International Diabetes Federation (IDF) Annual Congress in Abu Dhabi ...
London (ots/PRNewswire) - Medical Device companies operating in today's stringently regulated environment require comprehensive software systems and solutions that deliver robust functionality and support full compliance with regulatory requirements. In the area of software design for medical devices, adherence to the applicable regulations and standards is a complex and expensive process. In a recent survey conducted on ...
Hitachi Medical Systems Europe Holding AG
Abu Dhabi, Uae (ots/PRNewswire) - - Globally, cardiovascular disease (CVD) is the most common cause of death in people with type 2 diabetes[1] - 1 in 3 respondents considered themselves to be at low risk of CVD[2] - 1 in 6 respondents had never discussed type 2 diabetes and cardiovascular risk with a healthcare ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for U.S. based media - Expanded Fertility Technology portfolio highlights Merck's commitment to improve fertility treatment outcomes for patients - U.S. commercial availability expected in first half of 2018 Merck, a leading science and technology company, today ...
Bagsværd, Denmark (ots/PRNewswire) - - Switching to Tresiba® reduced the rate of hypoglycaemia by 67% in people with controlled blood sugar levels - In people with diabetes whose blood sugar was too high, switching to Tresiba® significantly improved blood sugar levels Switching to Tresiba® from another basal ...
Aachen (ots) - The Grünenthal Group announced today that Nucynta® (tapentadol) will be commercialized in the U.S. territory by Collegium Pharmaceutical, Inc., instead of Depomed, Inc., from 2018 onwards. In recent months, Depomed has been struggling to grow Nucynta®. Depomed executes its strategy to transform into a specialty pharmaceutical company with less focus ...
Abu Dhabi, Uae (ots/PRNewswire) - Once-daily Xultophy® (insulin degludec/liraglutide) was a better option to manage diabetes compared to multiple daily injections of insulin (basal-bolus regimen). This was reported by people with type 2 diabetes whose blood sugar was not controlled on insulin glargine U100 with ...
Copenhagen, Denmark (ots/PRNewswire) - New findings from an indirect comparison between Xultophy® and IGlarLixi published in the Journal of Medical Economics show that treatment with Xultophy® (insulin degludec/liraglutide) provides statistically significant greater reductions in blood sugar levels and body weight ...
Haifa, Israel (ots/PRNewswire) - INSIGHTEC (http://www.insightec.com/), the leader in MR-guided Focused Ultrasound (MRgFUS) therapy, announced today that the Taiwanese Food and Drug Administration (TFDA) has approved its Exablate Neuro system for the treatment of essential tremor in patients who do not respond to ...
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for UK-based media - Pivotal Phase III Javelin trial investigating avelumab as third-line treatment for patients with unresectable, recurrent or metastatic gastric cancer did not meet its pre-specified primary endpoint of superior overall survival ...
Québec, Canada (ots) - GenePOC Inc. (GenePOC), a member of the Debiopharm Group(TM), is proud to announce the launch of its 2nd FDA cleared assay in less than 6 months, GenePOC(TM) CDiff, for use on the revogene(TM) instrument. The GenePOC CDiff test targets the toxin B gene of toxigenic C. difficile strains in ...